Doxycycline revisited

Archives of Internal Medicine

Volumn 157, Issue 13, 1997, Pages 1421-1428

  Joshi, Nirmal ^a   Miller, Debra Q ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BORRELIA INFECTION; DRUG ABSORPTION; DRUG COST; DRUG EXCRETION; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RICKETTSIOSIS; SEXUALLY TRANSMITTED DISEASE; TOOTH COLOR; URINARY TRACT INFECTION;

EID: 0030855814     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.13.1421     Document Type: Review

References (139)

1. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995;273:241-242.
2. Joshi N, Milfred D. The use and misuse of new antibiotics: a perspective. Arch Intern Med. 1995; 155:569-577.
3. Duggar BM. Aureomycin: product of continuing search for new antibiotic. Ann N Y Acad Sci. 1948;51:177.
4. Finland M. Twenty-fifth anniversary of the discovery of Aureomycin: the place of the tetracyclines in antimicrobial therapy. Clin Pharmacol Ther. 1974;15:3-8.
5. Jones M, Comer JB, Cunha BA. Tetracyclines. In: Ristuccia AM, Cunha BA, eds. Antimicrobial Therapy. New York, NY: Raven Press; 1984:219-234.
6. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother. 1975;8:713-720.
7. Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics, I: tetracyclines. Am J Hosp Pharm. 1977; 34:49-57.
8. Connamacher RH, Mandel HG. Binding of tetracycline to the 30 S ribosomes and to polyuridylic acid. Biochem Biophys Res Commun. 1965;20:98.
9. Maxwell IH. Studies of the binding of tetracycline to ribosomes in-vitro. Mol Pharmacol. 1968; 4:25-37.
10. Suarez G, Nathans D. Inhibition of aminoacyl-tRNA binding to ribosomes by tetracycline. Biochem Biophys Res Commun. 1965;18:743.
11. Day LE. Tetracycline inhibition of cell-free protein synthesis, II: effect of the binding of tetracycline to the components of the system. J Bacteriol. 1966;92:197-203.
12. Pato ML. Tetracycline inhibits propagation of deoxyribonucleic acid replication and alters membrane properties. Antimicrob Agents Chemother. 1977;11:318-323.
13. Kucers A, Bennett NM. The Use of Antibiotics. 4th ed. Philadelphia, Pa: JB Lippincott; 1987: 979-1044.
14. Benveniste R, Davies J. Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem. 1973;42:471-506.
15. Bread NS Jr, Armentrout SA, Weisberger AS. Inhibition of mammalian protein synthesis by antibiotics. Pharmacol Rev. 1969;21:213-245.
16. Korkelia J. Antianabolic effect of tetracyclines. Lancet. 1971;1:974-975.
17. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355-366.
18. Davis CM, Vandersarl JV, Kraus EW. Tetracycline inequivalence: the importance of 96-hour testing. Am J Med Sci. 1973;265:69-74.
19. Meyer MC, Dann RE, Whyatt PL, Slywka GW. The bioavailability of sixteen tetracycline products. J Pharmacokinet Biopharm. 1974;2:287-297.
20. Saux MC, Mosser J, Pontagnier H, Leng B. Pharmacokinetics of doxycycline pylophosphate (PPD), hydrochloride (CHD) and base (DB). Eur J Drug Metab Pharmacokinet. 1981;6:3-10.
21. Schreiner A, Digranes A. Pharmacokinetics of limecycline and doxycycline in serum and suction blister fluid. Chemotherapy. 1985;31:261-265.
22. Malmborg AS. Bioavailability of doxycycline monohydrate: a comparison with equivalent doses of doxycycline hydrochloride. Chemotherapy. 1984;30:76-80.
23. Musher DM, Minuth JN, Thorsteinsson SB, Holmes T. Effectiveness of achievable urinary concentrations of tetracyclines against 'tetracycline resistant' pathogenic bacteria. J Infect Dis. 1975;131(suppl):S40-S44.
24. MacColloch CD, Richardson RA, Allwood GK. The penetration of doxycycline, oxytetracycline and minocycline into sputum. N Z Med J. 1974;80: 300-302.
25. Brihmer C, Brundin J. Levels of ampicillin and doxycycline in human oviduct mucosa and serum. Acta Obstet Gynecol Scand. 1983;62:231-234.
26. Brihmer C, Brundin J. Doxycycline in human oviduct mucosa and plasma 24-30 hours after an oral dose of 100 mg. Acta Obstet Gynecol Scand. 1985;64:529-530.
27. Whelton A, Blanco LJ, Carter CG, et al. Therapeutic implications of doxycycline and cephalothin concentrations in female genital tract. Obstet Gynecol. 1980;55:28-32.
28. Blanchard P, Rudhardt M, Fabre J. Behaviour of doxycycline in the tissues. Chemotherapy. 1975; 21:8-18.
29. Yim C, Flynn NN, Fitzgerald TF. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother. 1985;28:347-348.
30. Andersson H, Alestig K. The penetration of doxycycline into CSF. Scand J Infect Dis Suppl. 1976; 9:17-19.
31. MacDonald H, Kelly RG, Allen AS, et al. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther. 1973;14:852-861.
32. Houin G, Brunner F, Nebout T, et al. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol. 1983;16:245-252.
33. Whelton A, Schach von Wittenau M, Twomey TM, Walker WG, Bianchine JR. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int. 1974;5:365-371.
34. Letteri JM, Miraflor F, Tablante V, Siddiqi S. Doxycycline (Vibramycin) in chronic renal failure. Nephron. 1973;11:318-324.
35. Neu HC. A symposium on the tetracyclines: a major appraisal. Bull N Y Acad Med. 1978;54:141-155.
36. Vilde JL, Dournon E, Rajagopalan P. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother. 1986;30:743-748.
37. Havlichek D, Saravolatz L, Pohlod D. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob Agents Chemother. 1987;31:1529-1534.
38. Hammerschlag M. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994;38:1873-1878.
39. Bowie WR, Wang S, Alexander ER, et al. Etiology of nongonococcal urethritis. J Clin Invest. 1977;59:735-742.
40. Drugs for sexually transmitted diseases. Med Lett Drugs Ther. 1994;36:1-6.
41. Egerman RS. The tetracyclines. Obstet Gynecol Clin North Am. 1992;19:551-561.
42. Wolner-Hanssen P, Paavonen J, Kiviat N, Young M, Eschenbach DA, Holmes KK. Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline. Obstet Gynecol. 1988; 71:595-600.
43. Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep. 1993;42: 1-102.
44. Black RE. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis. 1990;12(suppl):S73-S79.
45. Alam AN, Alam NH, Ahmed T, et al. Randomised double-blind trial of single-dose doxycycline for treating cholera in adults. BMJ. 1990; 300:1619-1621.
46. Prevention and treatment of cholera. Med Lett Drugs Ther. 1991;33:107-108.
47. Rahaman MM, Majid MA, Alam AKM, Islam MR. Effects of doxycycline in actively purging cholera patients: a double-blind clinical trial. Antimicrob Agents Chemother. 1976;10:610-612.
48. Massarotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med. 1992; 92:396-403.
49. Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol. 1995;32:223-227.
50. Bella F, Font B, Uriz S, et al. Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever. Antimicrob Agents Chemother. 1990;34:937-938.
51. Raoult D. Treatment of Q fever. Antimicrob Agents Chemother. 1993;37:1733-1736.
52. Brown GW, Saunders JP, Singh S, Huxsoll DL, Shirai A. Single dose doxycycline therapy for scrub typhus. Trans R Soc Trop Med Hyg. 1978; 72:412-416.
53. Krause DW, Perine PL, McDade JE, Awoke S. Treatment of louse-borne typhus fever with chloramphenicol, tetracycline, or doxycycline. East Afr Med J. 1975;52:421-427.
54. Wallace RJ, Wiss K. Susceptibility of Mycobacterium marinum to tetracyclines and aminoglycosides. Antimicrob Agents Chemother. 1981; 20:610-612.
55. Kim R. Tetracycline therapy for atypical mycobacterial granuloma. Arch Dermatol. 1974;110:299.
56. Robin RB, Beatty RF, Dunn S, et al. Mycobacterium chelonei keratitis after radial keratotomy. Am J Ophthalmol. 1986;102:72-79.
57. McClain JB, Ballov WR, Harrison SM, Steinweg DL. Doxycycline therapy for leptospirosis. Ann Intern Med. 1984;100:696-698.
58. Takafuji ET, Kirkpatrick JW, Miller RN, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med. 1984;310: 497-500.
59. Acocella G, Bertrand A, Beytout J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother. 1989; 23:433-439.
60. Farrell ID, Hinchliffe PM, Robertson L. Sensitivity of Brucella spp to tetracycline and its analogues. J Clin Pathol. 1976;29:1097-1100.
61. Cisneros JM, Viciana P, Colmenero J, Pachon J, Martinez C, Alarcon A. Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother. 1990;34:881-883.
62. Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis. 1988; 53:29-34.
63. Seaton KG, Patz EF Jr, Goodman PC. Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. AJR Am J Roentgenol. 1995;164:589-591.
64. Harrison PV. A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol. 1988;13:242-244.
65. Plewig G, Petrozzi JW, Berendes V. Double-blind study of doxycycline in acne vulgaris. Arch Dermatol. 1970;101:435-438.
66. Levallois P, Rioux JE. Prophylactic antibiotic for suction curettage abortion: results of a clinical controlled trial. Am J Obstet Gynecol. 1988;158: 100-105.
67. Darj E, Stralin EB, Nilsson S. The prophylactic effect of doxycycline on postoperative infection rate after first-trimester abortion. Obstet Gynecol. 1987;70:755-758.
68. Simelaro JP, Ghen M, Ginsberg P. Evaluation of doxycycline in the treatment of acute sinusitis and bronchopulmonary disease. Curr Ther Res Clin Exp. 1980;27:769-773.
69. Jacobs P, Robinson R. Experiences with doxycycline in the management of acute respiratory tract infections. S Afr Med J. 1969;43:206-210.
70. Rogerson R. Doxycycline, a once-daily antibiotic in the treatment of chest infections in general practice. Br J Clin Pract. 1971;25:175-176.
71. Maesen FPV, Davies BI, van Noord JA. Doxycycline in respiratory infections: a reassessment after 17 years. J Antimicrob Chemother. 1986; 18:531-536.
72. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
73. Lyons HA, Thomas JS, Heurich AE, Shepherd DA, Wetmore SD. Efficacy of doxycycline in acute infections of the lower respiratory tract. Curr Ther Res Clin Exp. 1976;19:24-31.
74. Williams DN, Lockey JE, Boxmeyer M, et al. Treatment of urinary infections with doxycycline. In: Finegold SM, ed. Doxycycline: Recent Investigation and Clinical Experience. Amsterdam, the Netherlands: Excerpta Medica; 1977:51.
75. Peterman TA, Zaidi AA, Lieb S, Wioten JE. Incubating syphilis in patients treated for gonorrhea: a comparison of treatment regimens. J Infect Dis. 1994;170:689-692.
76. Centers for Disease Control and Prevention. Epididymitis. MMWR Morb Mortal Wkly Rep. 1993; 42:81-83.
77. Tornquist A, Edelund G, Forsgren A, Leandoer L, Olson S, Ursing G. Single-dose doxycycline prophylaxis and preoperative bacteriological culture in elective colorectal surgery. Br J Surg. 1981;68:565-568.
78. Hojer H, Wetterfors J. Systemic prophylaxis with doxycycline in surgery of the colon and rectum. Ann Surg. 1978;187:362-368.
79. Walder M, Leandoer L, Tornquist A, Forsgren A. Long-term effects on bacterial sensitivity patterns of preoperative antibiotic prophylaxis in colorectal surgery. Scand J Infect Dis. 1988;53 (suppl):59-64.
80. Pang LW, Boudereau EF, Limsomwong N, Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet. 1987;1:1161-1164.
81. McCulloch CAG, Birek P, Overall C, et al. Randomized, controlled trial of doxycycline in prevention of recurrent periodontitis in high-risk patients: antimicrobial activity and collagenase inhibition. J Clin Periodontol. 1990;17:616-622.
82. Nicolson GL, Rosenberg-Nicolson NL. Doxycycline treatment and Desert Storm. JAMA. 1995; 273:618-619.
83. Joshi RK, Atukorala DN, Abanmi A, Khamis OA, Haleem A. Successful treatment of Sweet's syndrome with doxycycline. Br J Dermatol. 1993; 128:584-586.
84. Viswalingham ND, Darougar S, Yearsley P. Oral doxycycline in the treatment of adult chlamydial ophthalmia. Br J Ophthalmol. 1986;70: 301-304.
85. Toth A, Lesser ML, Naus G, Brooks C, Adams D. Effect of doxycycline on pre-menstrual syndrome: a double-blind, randomized clinical trial. J Int Med Res. 1988;16:270-279.
86. Frucht-Pery J, Chayet AS, Feldman ST, Lin S, Brown SI. The effect of doxycycline on ocular rosacea. Am J Ophthalmol. 1989;107:434-435.
87. Smit JM, Ost MM, Groen AK, et al. A placebo-controlled study on the efficacy of aspirin and doxycycline in preventing clogging of biliary endoprostheses. Gastrointest Endosc. 1989;35: 485-489.
88. Bowie WR. Urethritis in males. In: Holmes KK, Mardh P-H, Sparling PF, Weiser PJ, eds. Sexually Transmitted Diseases. 2nd ed. New York, NY: McGraw-Hill Book Co; 1989:627-639.
89. Drugs for sexually transmitted diseases. Med Lett Drugs Ther. 1995;37:117-121.
90. Centers for Disease Control and Prevention. Pelvic inflammatory disease. MMWR Morb Mortal Wkly Rep. 1993;42:75-81.
91. Solhaug JH, Bergman L, Kylberg F. A randomized evaluation of single-dose chemoprophylaxis in elective colorectal surgery: a comparison between metronidazole and doxycycline. Ann Clin Res. 1983;15:15-20.
92. Johnson JR, Stamm WE. Diagnosis and treatment of acute urinary tract infections. Infect Dis Clin North Am. 1987;1:773-791.
93. Rosenstock J, Smith LP, Gurney M, et al. Comparison of single-dose tetracycline hydrochloride to conventional therapy of urinary tract infection. Antimicrob Agents Chemother. 1985; 27:652-654.
94. Brickfield FX, Carter WH, Johnson RE. Erythromycin in the treatment of acute bronchitis in a community practice. J Fam Pract. 1986;23:119-122.
95. Stott NCH, West RR. Randomised control trial of antibiotics in patients with cough and purulent sputum. BMJ. 1976;2:556-559.
96. Orr PH, Scherer K, MacDonald A, Moffatt MEK. Randomized placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature. J Fam Pract. 1993;36:507-512.
97. Pines A. Trimethoprim-sulfamethoxizole in the treatment and prevention of purulent exacerbations of chronic bronchitis. J Infect Dis. 1973; 128(suppl):706-709.
98. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995; 108(suppl):43S-52S.
99. Chodosh S, Tuck J, Pizzuto D. Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma. Scand J Infect Dis. 1988;53(suppl):22-28.
100. Bille J, Moser F, Francioli P. Etiology of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1986;5:389-390.
101. Pomila PV, Brown RB. Outpatient treatment of community-acquired pneumonia in adults. Arch Intern Med. 1994;154:1793-1802.
102. Berntsson E, Lagergard T, Strannegard O, Trollfors B. Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol Infect Dis.1986;5:446-447.
103. Erard P, Moser F, Wenger A, et al. Prospective study on community-acquired pneumonia diagnosed and followed up by private practitioners. In: Program and abstracts of the International Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2,1991; Chicago, III. Abstract 56.
104. American Thoracic Society Statement. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
105. Shea KW, Cunha BA, Ueno Y, Abumustafa F, Qadri SM. Doxycycline activity against Streptococcus pneumoniae. Chest. 1995;108:1775-1776.
106. Twartz JC, Shirai A, Selvarajv G, Saunders JP, Huxsoll JP, Groves MG. Doxycycline prophylaxis for human scrub typhus. J Infect Dis. 1982; 146:811-818.
107. Gudiol F, Pallares R, Caratulla J, et al. Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever. Antimicrob Agents Chemother. 1989;33:987-988.
108. Levy PY, Drancourt M, Etienne J, et al. Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis. Antimicrob Agents Chemother. 1991;35:533-537.
109. Ljungberg B, Christensson B, Grubb R. Failure of doxycycline treatment in aquarium-associated Mycobacterium marinum infections. Scand J Infect Dis. 1987;19:539-543.
110. Dalovisio JR, Pankey GA, Wallace RJ, Jones DB. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis. 1981;3:1068-1074.
111. Kitamura S, Sugiyama Y, Izumi T, et al. Intrapleural doxycycline for control of malignant pleural effusion. Curr Ther Res Clin Exp. 1981;4:515-521.
112. Dembry LM, Uzokwe K, Zervos MJ. Control of endemic glycopeptide-resistant enterococci. Infect Control Hosp Epidemiol. 1996;17:286-292.
113. Montecalvo MA, Horowitz H, Carbonaro C, et al. Effect of rovobrocin containing antibiotic regimens on infection and colonization with vancomycin-and ampicillin-resistant Enterococcus faecium (VAREF). In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: October 4-7, 1994; Orlando, Fla. Abstract J153.
114. Lo S-C, Shih JW, Newton PB, et al. Virus-like infectious agent (VLIA) is a novel pathogenic mycoplasma: Mycoplasma incognitus. Am J Trop Med Hyg. 1989;41:586-600.
115. Hinton NA. The effect of oral tetracycline HCI and doxycycline on the intestinal flora. Curr Ther Res Clin Exp. 1970;12:341-352.
116. Clendinnen IJ. Doxycycline in the treatment of chronic lung infections. Med J Aust. 1974;1:9-11.
117. Lanza FL. Esophageal ulceration produced by doxycycline. Curr Ther Res Clin Exp. 1988;44: 475-484.
118. Schneider R. Doxycycline esophageal ulcers. Am J Dig Dis. 1977;22:805-807.
119. Shiff AD. Doxycycline-induced esophageal ulcers in physicians. JAMA. 1986;256:1893.
120. Doxycycline and renal failure. Med Lett Drugs Ther. 1972;14:3-4.
121. Orr LH, Rudisill E, Brodkin R, Hamilton RW. Exacerbation of renal failure: association with doxycycline. Arch Intern Med. 1978;138:793-794.
122. Shwachman H, Fekete E, Kulczycki LL, Foley GE. The effect of long-term antibiotic therapy in patients with cystic fibrosis of the pancreas. Antibiot Annu. 1958;59:692.
123. Wallman IS, Hilton HB. Teeth pigmentation by tetracycline. Lancet. 1962;1:827.
124. Porter PJ, Sweeney EA, Golan H, Kass EH. Controlled study of the effect of prenatal tetracycline on primary dentition. Antimicrob Agents Chemother. 1965;5:668-671.
125. Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracyclines. AJDC. 1963;105:453.
126. Edwards R. Doxycycline and photosensitivity. N Z Med J. 1987;100:640.
127. Council on Drugs. Evaluation of a new antibacterial agent: doxycycline monohydrate and doxycycline hyclate (Vibramycin). JAMA. 1969;209: 549-550.
128. Frank SB, Choen HJ, Minken W. Photo-onycholysis due to tetracycline hydrochloride and doxycycline. Arch Dermatol. 1971;103:520-521.
129. Ramelli G. Photo-onycholysis following doxycycline hyclate. Cutis. 1972;10:155-156.
130. Curley RK, Verbov JL. Stevens-Johnson syndrome due to tetracyclines: a case report (doxycycline) and review of the literature. Clin Exp Dermatol. 1987;12:124-125.
131. Trueb RM, Burg G. Acute generalized exanthematous pustulosis due to doxycycline. Dermatology. 1993;186:75-78.
132. Neuvonen PJ. Interactions with absorption of tetracyclines. Drugs. 1976;11:45-54.
133. Venho VMK, Salonen RO, Mattila MJ. Modification of the pharmacokinetics of doxycycline in man by ferrous sulfate or tissues. Chemotherapy. 1975;21:8-18.
134. Jonkman JHG, Van Der Boon WJV, Schoenmaker R, Holtkamp A, Hempenius J. No influence of doxycycline on theophylline pharmacokinetics. Ther Drug Monit. 1985;7:92-94.
135. Caraco Y, Rubinow A. Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration. Ann Pharmacother. 1992;26:1084-1085.
136. Mattila MJ, Laisi U, Linnoila M, Salonen R. Effect of alcoholic beverages on the pharmacokinetics of doxycycline in man. Acta Pharmacol Toxicol (Copenh). 1982;50:370-373.
137. Nguyen VX, Nix DE, Gillikin S, et al. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimicrob Agents Chemother. 1989;33:434-436.
138. Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247:2266-2267.
139. Neely JL, Abate M, Swinker M, et al. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone and endogenous progesterone. Obstet Gynecol. 1991;77:416-420.